This is a routine resale registration that does not change the company's fundamentals. Monitor for any selling stockholder sales that could create near-term overhang, but the Resale Organization Agreement's daily volume cap (15% of 10-day average volume) and EIB priority period should limit market disruption. The earnout shares are contingent on FDA approval and commercial milestones, so no immediate dilution from those.
Price Chart
Executive Summary
Stereotaxis filed an S-3 shelf registration statement to register up to 19,449,603 shares of common stock for resale by selling stockholders who received the shares in the acquisition of Robocath. The registration covers 6,269,628 closing shares already issued and up to 13,179,975 earnout shares tied to regulatory and commercial milestones, with a maximum aggregate deal value of $45 million. The filing is a routine contractual obligation to register shares for resale, not a primary offering by the company.
Key Facts
- S-3 registers up to 19,449,603 shares for resale by selling stockholders from the Robocath acquisition.
- Includes 6,269,628 closing shares (issued July 7, 2026) and up to 13,179,975 earnout shares tied to milestones.
- Total acquisition consideration up to $45 million, with $20 million upfront (stock and cash) and up to $25 million in earnouts.
- Registration fee calculated on $31.5 million maximum aggregate offering price at $1.62/share (July 14, 2026 closing price $1.60).
- Share cap of 19.9% of pre-closing outstanding shares limits total issuable shares under the acquisition agreement.
- Company receives no proceeds from this resale registration.
Financial Impact
Registration covers up to 19.9% of pre-closing shares outstanding, with a maximum aggregate offering price of $31.5 million based on the $1.62 calculation price. No new capital raised for the company.
Risk Factors
- Potential overhang from selling stockholders reselling shares, though volume caps mitigate this.
- Earnout shares could add dilution if milestones are achieved, but this is contingent and uncertain.
- Integration risk from the Robocath acquisition remains, separate from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-033396 |
| Exhibit: ex4-3.htm | 0001493152-26-033396 |
| Exhibit: ex2-2.htm | 0001493152-26-033396 |
| Exhibit: ex10-1.htm | 0001493152-26-033396 |
| Exhibit: ex107.htm | 0001493152-26-033396 |
| Exhibit: ex24-1.htm | 0001493152-26-033396 |
| Exhibit: ex5-1.htm | 0001493152-26-033396 |
| Exhibit: ex23-1.htm | 0001493152-26-033396 |
| Document: forms-3.htm | 0001493152-26-033396 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $1.39 $1.18 | ▼ −15.11% | ▼ −13.92% | $0.9900 (−28.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $0.9900 (+28.26%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $0.9900 (+28.26%) |
Aug 11, 2026 10w ago | Press Release | $1.40 $1.30 | ▼ −7.14% | ▼ −5.25% | $0.9900 (−29.29%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▲ +16.36% | ▲ +19.98% | $0.9900 (+40.00%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▼ −16.36% | ▼ −19.98% | $0.9900 (−40.00%) |
Jul 9, 2026 15w ago | 8-K | $1.74 $1.36 | ▼ −21.84% | ▼ −24.08% | $0.9900 (−43.10%) |
May 12, 2026 23w ago | 8-K | $1.85 $1.82 | ▲ +1.62% | ▲ +1.01% | $0.9900 (+46.49%) |
May 12, 2026 23w ago | Press Release | $1.85 $1.82 | ▼ −1.62% | ▼ −1.01% | $0.9900 (−46.49%) |
Apr 21, 2026 26w ago | Press Release | $1.92 $1.78 | ▼ −7.29% | ▼ −12.21% | $0.9900 (−48.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers